A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

  • STATUS
    Not Recruiting
  • participants needed
    64
  • sponsor
    Eli Lilly and Company
Updated on 24 June 2021
Investigator
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Primary Contact
Highlands Oncology Group (1.2 mi away) Contact
+43 other location

Summary

The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.

Details
Condition Small Cell Lung Cancer
Treatment LY3295668 Erbumine
Clinical Study IdentifierNCT03898791
SponsorEli Lilly and Company
Last Modified on24 June 2021

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note